Catalyst Pharmaceuticals (CPRX) Stock Falls on Q4 2025 Earnings

Catalyst Pharmaceuticals (CPRX) reported fourth-quarter 2025 results with revenue above expectations and a strong cash position.

Key financials:

Revenue: $152.6 million (up 7.61% year‑over‑year).

Gross profit: $126.5 million (up 5.29% year‑over‑year).

Operating profit: $61.8 million (down 1.59% year‑over‑year).

Net income attributable to common shareholders: $52.7 million (down 5.79% year‑over‑year).

Diluted earnings per share: $0.41 (down 6.82% year‑over‑year).

Cash flow and balance sheet highlights:

Cash from operating activities: $44.9 million (down 36.66% year‑over‑year).

Capital expenditures (purchases of property, plant and equipment): $32 thousand (down 63.64% year‑over‑year).

Cash and cash equivalents: $709.2 million (up 37.02% year‑over‑year).

Total liabilities: $149.7 million (up 20.95% year‑over‑year).

Cost of sales: $26.1 million (up 20.47% year‑over‑year).

Comparisons and market reaction:

Revenue vs. estimate: actual $152.6 million vs. estimate $144.9 million (about a 5.3% beat).

EPS vs. estimate: actual $0.41 vs. estimate $0.34 (about 19.6% above expectations).

Stock price change since market close: down 4.06%.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Catalyst Pharmaceuticals Inc. Insider Trading Activity

Catalyst Pharmaceuticals Inc. insiders have traded $CPRX stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.

Here’s a breakdown of recent trading of $CPRX stock by insiders over the last 6 months:

BRIAN ELSBERND (Chief Compliance/Legal Officer) has made 0 purchases and 4 sales selling 120,000 shares for an estimated $2,504,200.
MOLLY HARPER has made 0 purchases and 3 sales selling 26,746 shares for an estimated $621,920.
DAVID S TIERNEY sold 26,000 shares for an estimated $525,200
CARMEN JEFFREY DEL (Chief Commercial Officer) sold 10,983 shares for an estimated $256,244

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

Catalyst Pharmaceuticals Inc. Hedge Fund Activity

We have seen 176 institutional investors add shares of Catalyst Pharmaceuticals Inc. stock to their portfolio, and 219 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JANUS HENDERSON GROUP PLC added 1,147,565 shares (+200.6%) to their portfolio in Q4 2025, for an estimated $26,784,167
MORGAN STANLEY added 1,089,775 shares (+59.1%) to their portfolio in Q4 2025, for an estimated $25,435,348
RENAISSANCE TECHNOLOGIES LLC removed 894,753 shares (-25.2%) from their portfolio in Q4 2025, for an estimated $20,883,535
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 829,923 shares (-74.8%) from their portfolio in Q4 2025, for an estimated $19,370,402
MACQUARIE GROUP LTD removed 761,740 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $17,779,011
PACER ADVISORS, INC. removed 620,801 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $14,489,495
GLENMEDE INVESTMENT MANAGEMENT, LP added 603,084 shares (+781.8%) to their portfolio in Q3 2025, for an estimated $11,880,754

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Catalyst Pharmaceuticals Inc. Analyst Ratings

Wall Street analysts have issued reports on $CPRX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Citigroup issued a "Buy" rating on 11/07/2025

To track analyst ratings and price targets for Catalyst Pharmaceuticals Inc., check out Quiver Quantitative's $CPRX forecast page.